Onconova Therapeutics, Inc.
Records under this name other than the patents Onconova Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.
Back to Onconova Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,576,050 | Methods and Compostions for Treatment of Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 12,156,856 | Formulation of (E)-2,4,6-Trimethoxystyryl-3-[(CARBOXYMETHYL)AMINO]-4-Methoxybenzylsulphone with Enhanced Stability and Bioavailability Formerly held In force · High confidence | In force | High confidence | |
| US 10,098,862 | Formulations with Enhanced Stability and Bioavailability for Administantion of (E)-2,6-Dialkoxystyryl 4-Substituted Benzylsulfones Formerly held Lapsed on the fee record Ended Oct 16, 2026 · Low confidence | Lapsed on the fee record | Ended Oct 16, 2026 | Low confidence |
| US 11,382,877 | Formulation of (E)-2,4,6-Trimethoxystyryl-3-[(CARBOXYMETHYL)AMINO]-4-Methoxybenzylsulphone with Enhanced Stability and Bioavailability Formerly held Lapsed on the fee record Ended Jul 12, 2026 · High confidence | Lapsed on the fee record | Ended Jul 12, 2026 | High confidence |
| US 8,735,620 | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders Lapsed on the fee record Ended May 27, 2026 · USPTO record | Lapsed on the fee record | Ended May 27, 2026 | USPTO record |
| US 7,932,242 | Substituted Phenoxy-And Phenylthio-Derivatives for Treating Proliferative Disorders Term ended Ended no later than Mar 15, 2025 · Medium confidence | Term ended | Ended no later than Mar 15, 2025 | Medium confidence |
| US 7,744,889 | Alpha, Beta-Unsaturated Sulfoxides for Treating Proliferative Disorders Formerly held Term ended Term ended Jan 11, 2025 · High confidence | Term ended | Term ended Jan 11, 2025 | High confidence |
| US 8,324,190 | Treatment of Proliferative Disorders with Amino-Substituted (E)-2,6- Dialkoxystyryl 4-Substituted Benzylsulfones Formerly held Term ended Ended no later than Jan 11, 2025 · Low confidence | Term ended | Ended no later than Jan 11, 2025 | Low confidence |
| US 7,598,232 | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders Term ended Term ended Dec 10, 2024 · USPTO record | Term ended | Term ended Dec 10, 2024 | USPTO record |
| US 6,646,009 | N-(ARYL)-2-Arylethenesulfonamides and Therapeutic Uses Thereof Formerly held Term ended Term ended Feb 28, 2022 · High confidence | Term ended | Term ended Feb 28, 2022 | High confidence |